TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07412704: A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$351,900

Rescue Site Savings

+$234,600

Unlock Full NCT07412704 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07412704 Rescue Dossier →